Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain | MicrobiomeTrials← Back to trialsNCT02522611
Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2026-06-27Est. Completion: 2026-12-01
Enrollment target: 30 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Myofascial Pain Dysfunction SyndromeTrigger Points, MyofascialTrigger Point in Trapezius Muscle
Brief Summary
Myofascial pain syndrome (MPS) is a common musculoskeletal condition characterized by active trigger poin…
Kyrenia, CyprusEst. completion Dec 2026
Refractory Chronic Cluster Headache
The occipital nerve stimulation (ONS) is used to treat patients with refractory primary chronic headache but its mechani…
Clermont-Ferrand, FranceCompleted Nov 17, 2015